New findings link estrogen and T cell immune response to autoimmune inflammation

Women are more prone to the development of autoimmune diseases. The female hormone estrogen is likely to affect the immune system. A team of scientists from Turku Center for Biotechnology and University of Georgia reported new findings related to the involvement of estrogen hormone receptor in autoimmune diseases.

The incidence of autoimmune diseases such as MS, RA, and SLE is higher in women than in men. The estrogen hormone secreted in women may contribute to the pathogenesis of these diseases.

A research team led by Docent Zhi Chen from Turku Center for Biotechnology of the University of Turku has collaborated with researchers from the University of Georgia, United States to address the long-standing issue of hormonal effect on autoimmune diseases.

Estrogen hormone shows its action on cells mostly through estrogen receptor alpha (ERα). Researchers from Turku generated mice with ERα protein specifically deleted in T cells.

"The eureka moment of our research is that in a mouse model of human inflammatory bowel disease, transfer of naive T helper cells from ERα deficient mice did not succumb to colitis, unlike transfer from their counterparts," Docent Zhi Chen tells.

"Furthermore, using cutting-edge technique RNA sequencing approach combined with in vitro and in vivo experiments, we discovered that ERα regulates multiple aspects of T cell function, including T cell activation, proliferation and survival," Chen adds.

Regulatory T cells are group of T cells that help in preventing autoimmune diseases. The researchers found that ERα influences the function and differentiation of regulatory T cells.

Imran Mohammad, Inna Starskaia, Tamas Nagy, Jitao Guo, Emrah Yatkin, Kalervo Väänänen, Wendy T Watford, and Zhi Chen.
Estrogen receptor α contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation.
Sci. Signal. 17 Apr 2018: Vol. 11, Issue 526, eaap9415. doi: 10.1126/scisignal.aap9415.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...